Literature DB >> 11061947

Prognostic value of cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s in surgically treated patients with prostate cancer.

A N Vis1, M A Noordzij, K Fitoz, M F Wildhagen, F H Schröder, T H van der Kwast.   

Abstract

PURPOSE: Molecular tissue markers may give the clinician additional information about patients with prostate cancer at risk for treatment failure after retropubic radical prostatectomy. We substantiate the prognostic value of 3 tissue markers, the cell cycle proteins p27(kip1) and MIB-1, and the cell adhesion protein CD44s, in addition to more conventional pathological prognosticators in an historical (before prostate specific antigen) cohort of patients with prostate cancer.
MATERIALS AND METHODS: Representative tumor sections from 92 patients who underwent retropubic radical prostatectomy were immunohistochemically stained with antibodies against p27(kip1), MIB-1 (Ki-67) and CD44s, and assessed in a semiquantitative manner. Gleason score and pathological tumor stage were recorded. All variables were correlated with clinical progression and disease specific survival on univariate and multivariate analyses.
RESULTS: On univariate analysis low (less than 50%) p27(kip1), high (10% or greater) MIB-1 and loss of CD44s expression were significantly associated with clinical outcome parameters, although MIB-1 did not reach statistical significance for disease specific survival. All 3 molecules were highly correlated with Gleason score and pathological tumor stage. Multivariate analysis showed that low p27kip1 was independent of grade and stage in predicting clinical recurrence (p <0.001) and disease specific survival (p = 0.045), while loss of CD44s was an additional independent prognostic factor for clinical recurrence (p = 0.02).
CONCLUSIONS: Reduced p27(kip1) expression is an independent predictor of poor outcome in prostate cancer, while MIB-1 is not. Decreased expression of CD44s yields additional information in predicting clinical recurrence. These tissue markers may identify patients at risk for disease recurrence after retropubic radical prostatectomy who may benefit from adjuvant therapy.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061947

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  24 in total

Review 1.  Mouse models of prostate cancer: picking the best model for the question.

Authors:  Magdalena M Grabowska; David J DeGraff; Xiuping Yu; Ren Jie Jin; Zhenbang Chen; Alexander D Borowsky; Robert J Matusik
Journal:  Cancer Metastasis Rev       Date:  2014-09       Impact factor: 9.264

2.  Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy.

Authors:  Romain Mathieu; Shahrokh F Shariat; Christian Seitz; Pierre I Karakiewicz; Harun Fajkovic; Maxine Sun; Yair Lotan; Douglas S Scherr; Ashutosh Tewari; Francesco Montorsi; Alberto Briganti; Morgan Rouprêt; Ilaria Lucca; Vitaly Margulis; Michael Rink; Luis A Kluth; Malte Rieken; Alexander Bachman; Evanguelos Xylinas; Brian D Robinson; Karim Bensalah; Markus Margreiter
Journal:  World J Urol       Date:  2014-10-26       Impact factor: 4.226

3.  Phenyl-methylene hydantoins alter CD44-specific ligand binding of benign and malignant prostate cells and suppress CD44 isoform expression.

Authors:  Kui Yang; Yaqiong Tang; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2010-01-01       Impact factor: 4.060

4.  Subcellular localization of p27 and prostate cancer recurrence: automated digital microscopy analysis of tissue microarrays.

Authors:  Viju Ananthanarayanan; Ryan J Deaton; Anup Amatya; Virgilia Macias; Ed Luther; Andre Kajdacsy-Balla; Peter H Gann
Journal:  Hum Pathol       Date:  2011-02-02       Impact factor: 3.466

Review 5.  p27: a barometer of signaling deregulation and potential predictor of response to targeted therapies.

Authors:  Seth A Wander; Dekuang Zhao; Joyce M Slingerland
Journal:  Clin Cancer Res       Date:  2010-10-21       Impact factor: 12.531

6.  Silibinin suppresses CD44 expression in prostate cancer cells.

Authors:  Alina M Handorean; Kui Yang; Eric W Robbins; Thomas W Flaig; Kenneth A Iczkowski
Journal:  Am J Transl Res       Date:  2009-01-01       Impact factor: 4.060

7.  Reduction of PTEN and p27kip1 expression correlates with tumor grade in prostate cancer. Analysis in radical prostatectomy specimens and needle biopsies.

Authors:  Tina Dreher; Hanswalter Zentgraf; Ulrich Abel; Alexandra Kappeler; Maurice S Michel; Uwe Bleyl; Rainer Grobholz
Journal:  Virchows Arch       Date:  2004-04-29       Impact factor: 4.064

Review 8.  Hyaluronan and hyaluronidase in genitourinary tumors.

Authors:  Melanie A Simpson; Vinata B Lokeshwar
Journal:  Front Biosci       Date:  2008-05-01

9.  MicroRNAs 373 and 520c are downregulated in prostate cancer, suppress CD44 translation and enhance invasion of prostate cancer cells in vitro.

Authors:  Kui Yang; Alina M Handorean; Kenneth A Iczkowski
Journal:  Int J Clin Exp Pathol       Date:  2008-11-26

10.  Stable alterations of CD44 isoform expression in prostate cancer cells decrease invasion and growth and alter ligand binding and chemosensitivity.

Authors:  Kui Yang; Yaqiong Tang; Gabriel K Habermehl; Kenneth A Iczkowski
Journal:  BMC Cancer       Date:  2010-01-14       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.